Vaughan David Investments LLC IL acquired a new position in Organon & Co. (NYSE:OGN) during the second quarter, according to its most recent filing with the SEC. The firm acquired 30,771 shares of the company’s stock, valued at approximately $931,000.
Other hedge funds have also modified their holdings of the company. MCF Advisors LLC bought a new stake in shares of Organon & Co. in the 2nd quarter worth approximately $26,000. HHM Wealth Advisors LLC bought a new stake in shares of Organon & Co. in the 2nd quarter worth approximately $26,000. Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Organon & Co. in the 2nd quarter valued at approximately $86,000. Optimum Investment Advisors purchased a new position in shares of Organon & Co. in the 2nd quarter valued at approximately $27,000. Finally, Center for Financial Planning Inc. purchased a new position in shares of Organon & Co. in the 2nd quarter valued at approximately $30,000.
OGN stock opened at $32.94 on Tuesday. Organon & Co. has a 1-year low of $27.25 and a 1-year high of $38.75. The business has a fifty day simple moving average of $32.10.
The firm also recently declared a quarterly dividend, which was paid on Monday, September 13th. Stockholders of record on Monday, August 23rd were paid a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 3.40%. The ex-dividend date was Friday, August 20th.
In other Organon & Co. news, Director Ma. Fatima Francisco purchased 3,000 shares of the firm’s stock in a transaction dated Thursday, August 19th. The stock was purchased at an average price of $33.79 per share, for a total transaction of $101,370.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
A number of research analysts have recently commented on the company. Truist assumed coverage on Organon & Co. in a research note on Wednesday, June 2nd. They issued a “buy” rating and a $48.00 target price for the company. Citigroup raised their target price on Organon & Co. from $35.00 to $43.00 and gave the company a “buy” rating in a research note on Wednesday, August 18th. The Goldman Sachs Group started coverage on Organon & Co. in a research note on Thursday, June 3rd. They set a “neutral” rating and a $35.00 price objective for the company. Evercore ISI started coverage on Organon & Co. in a research note on Thursday, June 10th. They set an “outperform” rating for the company. Finally, Morgan Stanley lifted their price objective on Organon & Co. from $33.00 to $35.00 and gave the company an “equal weight” rating in a research note on Monday, August 16th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $40.00.
About Organon & Co.
Organon & Co, a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
Featured Article: The limitations of an equal weight rating
Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN).
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.